Product Images Pavblu

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 22 images provide visual information about the product associated with Pavblu NDC 55513-056 by Amgen, Inc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1 - pavblu 01

This is a description of a syringe cap with a Luer Lock and a dosing line of 0.05 mL. It also features a plunger with a finger grip and a plunger rod.*

Figure 2 - pavblu 02

Figure 3 - pavblu 03

Figure 4 - pavblu 04

Figure 5a - pavblu 05

This text appears to be a list of components related to an air bubble dosing system, including a plunger, dome, and edge. This system may be used for dosing solutions through a line.*

Figure 5b - pavblu 06

This is not available.*

Figure 6 - pavblu 07

Figure 7 - pavblu 08

Figure 8a - pavblu 09

Figure 8b - pavblu 10

Figure 9a & 9b - pavblu 11

Figure 10a - pavblu 12

Figure 10b - pavblu 13

Figure 11 - pavblu 14

Figure 12a & 12b - pavblu 15

This text provides instructions for administering a dose of 0.05 mL using a syringe. It includes guidance on expelling air bubbles and excess drug from the solution before administering the medication. The text also references Figure 12a and Figure 12b, which likely show visual aids for proper administration techniques.*

Figure 13 - pavblu 16

This appears to be a chart showing the mean change in visual acuity over different weeks for different treatments such as Aflibercept and Ranibizumab. The chart lists the number of letters read, the weeks, and the dosages of the treatments. The data seems to compare visual acuity changes between Aflibercept injections every 8 weeks, Aflibercept injections every 4 weeks, and Ranibizumab injections every 4 weeks.*

Figure 14 - pavblu 17

Mean Change in Visual Acuity data from the COPERNICUS and GALILEO studies where patients were treated with Aflibercept 2 mg Q4 weeks compared to a control group. The visual acuity improvement after 20 weeks and 24 weeks is demonstrated in the study results.*

Figure 15 - pavblu 18

This text describes a comparison between two groups over a period of weeks, one being treated with Aflibercept 2 mg every 4 weeks, while the other group serves as the control. It indicates different timepoints and potentially outcomes being measured in the study.*

Figure 16 - pavblu 19

Figure 17 - pavblu 20

The text provides data about the proportion of patients at various time points during the study. It includes percentages such as 62.7%, 59.3%, 55.2%, 45.5%, 40.6%, 6.8%, 6.0%, 7.5%, 79.9%, 65.2%, 15.0%. The study mentions weeks 8, 12, 24, 40, and 52. Additionally, it appears to compare a control group (sham) with two groups receiving Aflibercept intervention in 2016 and 208.*

PRINCIPAL DISPLAY PANEL - 0.05 mL Syringe Carton - pavblu 21

This description provides information about a medication called PAVBLU™, which comes in a prefilled syringe containing 2 mg of aflibercept-ayyh solution. The medication is not for sale and is intended for intravitreal injection. It includes details about the contents of the syringe and storage instructions, such as keeping it refrigerated and protecting it from light. Recommended dosage details are also mentioned, and it is advised to see the prescribing information for further guidance. Additionally, the text indicates that the product should be stored in its original carton and discarded if unused.*

PRINCIPAL DISPLAY PANEL - 0.05 mL Vial Carton - pavblu 22

This is a description of a medication labeled with NDC 55513-065-01. It contains 2mg in 0.05 mL of a 40 mg/mL solution for Intravitreal Injection. It comes in a single-dose vial and is a sterile solution without antimicrobial preservatives. The label advises keeping it out of reach of children and discarding any unused portion. The text also includes the letter "R Only."*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.

Table of Contents